Exit / M&A
Beaten Zone Team Expands
Defence-focused VC firm Beaten Zone Venture Partners adds two people: ex-Army general Mick Ryan as advisor, and Peta Ellis rejoining Steve Baxter's team alongside existing staff.
Company
Johns Hopkins University
Baltimore, OS
Funding history
Investors
Every investor coverage indicates participated in a round Johns Hopkins University raised.
What Johns Hopkins University bought
Companies Johns Hopkins University acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
People
| Name | Role | Sources |
|---|---|---|
| Dr Brian Hearing | Scientist (former) | @AuManufacturing |
Coverage
Stories naming Johns Hopkins University. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Unnamed stage
$15m
The biotech startup behind the petri dish of brain cells that played Pong just raised $15 million
Melbourne synthetic biology company Cortical Labs has secured US$10 million (A$15 million), led by Horizons Ventures with four co-investors, to advance its brain-cell computing platform commercially and meet pre-orders.
Also TechCrunch Australia·Forbes Australia·SmartCompany·Forbes Australia·Crunchbase News·Crunchbase News
News
Glyscend Therapeutics Releases New Phase 1 Biomarker Results and Initiates Phase 2 Clinical Trial under an IND for GLY-200 as a Potential First-in-Class Type 2 Diabetes Treatment
Glyscend reports encouraging Phase 1 biomarker data for its diabetes drug GLY-200, announces US FDA clearance of its investigational new drug application, and has begun enrolling patients in a Phase 2 trial.
Key hire
Glyscend Therapeutics Announces Completion of Phase 1 Clinical Trial of its Oral, Gut-restricted, Polymer Therapeutic, GLY-200, as a Potential Type 2 Diabetes Treatment
Biotech Glyscend reports its Phase 1 trial of GLY-200 for type 2 diabetes completed safely, and appoints Mark Fineman as Chief Development Officer ahead of a planned US regulatory filing and Phase 2 work.
Key hire
Glyscend Therapeutics Announces Completion of Phase 1 Clinical Trial of its Oral, Gut-restricted, Polymer Therapeutic, GLY-200, as a Potential Type 2 Diabetes Treatment
Glyscend reports its GLY-200 Phase 1 trial finished safely in healthy volunteers, with Phase 2 planned, and appoints Mark Fineman as Chief Development Officer to lead its metabolic disease programs.